

# Folate-functionalized Polymeric Micelle for Combinatorial Therapy to Overcome Drug Resistant Breast Cancer

Graham Temples, Jeoung Soo Lee.

Drug Design, Development and Delivery Laboratory, Department of Bioengineering,  
Clemson University, Clemson, SC 29634, USA

**Statement of Purpose:** Cancer continues to be one of the leading causes of death worldwide, with breast cancers accounting for nearly fourteen percent of all cancer related deaths in women.<sup>1,2</sup> Prognosis is intimately tied to surface protein expressions, often growth promoting elements such as Human Epidermal Factor Receptor-2 or drug-resistance inducing P-glycoprotein (P-gp) are overexpressed.<sup>3,4</sup> With breast cancers possessing high nucleic acid synthesis requirements, another marker often overexpressed is folate receptor alpha (FA +), a protein with a fortunately limited distribution elsewhere in the body.<sup>5</sup> This potential expression differential was exploited as a means to selectively target breast cancer by conjugating a folate (FA) moiety to the surface of Pgp (Poly (lactic-co-glycolic acid)-graft-polyethylenimine) micelle for targeted delivery of siRNA and chemotherapeutic agents.

**Methods:** Pgp was synthesized and characterized by <sup>1</sup>H-NMR and GPC previously in our 4D Lab.<sup>6</sup> To synthesize FA-Pgp, FA was conjugated to the surface of Pgp using Mal-PEG-SVA as a spacer. Following synthesis and purification, the structure of FA-Pgp was characterized by <sup>1</sup>H-NMR. The feasibility of Pgp and FA-Pgp as a nucleic acid carrier was evaluated using the Monster Green Fluorescent Protein phMGFP Vector (pGFP (Promega), 2 µg/well) in MCF-7 (FA +) and MDA-MB-468 (FA -) cells in 10% serum-containing media. Transfections were performed by complexing pGFP with Pgp, FA-Pgp, or Pgp/FA-Pgp mixed micelle (1/2 w/w ratio) at various N/P ratios and subsequently applying the solutions to MCF-7 (FA +), MDA-MB-468 (FA -) (breast cancer) cells. In order to further characterize target specificity of FA-functionalized micelle, transfections were performed by complexing pGFP with FA-Pgp and mixed micelles at N/P ratios of 25:1 in the presence of free FA, to act as a competitive inhibitor of FA mediated internalization pathway, in MCF-7 (FA +) and MDA-MB-468 (FA -) cells. Complexes of pGFP with polyethylenimine and

folate functionalized polyethylenimine at N/P ratio of 5/1 were used as positive controls. At 48 hours post-transfection, cells were collected and transfection efficiency was assessed by flow cytometry and epifluorescent microphotography, while cytotoxicity was assessed by MTT assays.

**Results:** Folic acid was successfully conjugated to Pgp and confirmed via <sup>1</sup>H-NMR. FA-Pgp exhibited selectivity when comparing the transfection efficiencies against Pgp in folate receptor alpha positive (MCF-7) and negative breast cancer cell lines (MDA-MB-468). Transfections with FA-Pgp exhibited substantial decrease in efficiency compared to Pgp in MDA-MB-468 (FA-) cells, with less reductive effect noted in MCF-7 (FA +) cells. A mixed micelle restored transfection in a manner proportional to Pgp content (Fig 1). In the presence of free FA, transfection efficacies of both FA-Pgp and mixed micelles were substantially impaired in MCF-7 (FA +) but not in MDA-MB-468 (FA -) cells (Fig 2), indicating free FA performed as competitive inhibitor against FA-Pgp, providing additional evidence for pathway dependent sequestration.

**Conclusions:** Currently, we are evaluating FA-Pgp or FA-Pgp/Pgp mixed micelle as a siRNA delivery carrier using siRNA targeting P-glycoprotein (P-gp siRNA) in MDA-MB-435 ADR (FA+). Future work includes utilizing combinatorial therapy of micelle/P-gp siRNAs with chemotherapeutics such as Doxorubicin or Paclitaxel to overcome drug resistance in breast cancers.

**Acknowledgement:** Research reported in this publication was supported by NIGMS of the National Institutes of Health under award number 5P20GM103444-07.

**References:** 1. Sun et al, *Nanoscale*, 5:845-859 (2013) 2. Sayed et al, *Ultrasonics*, 53:979-91 (2013) 3. Hicks and Kulkarni, 129:263-273 (2008). 4. Thomas and Coley. *Cancer Control*. 10:159-165 (2003). 5. Meier et al, *Radiology*. 255:527-535 (2010). 6 Lee et al. *Trans SFB* p.917 (2010)




Figure 1: Transfection efficiency of various polyplexes in MCF 7 (FA+) and MBA-MB-468 (FA-) cells in 10% serum condition. Plasmid: pGFP, PEI or FA-PEI polyplexes: 5/1 N/P ratio; Pgp, FA-Pgp, FA-Pgp 1:2 (FA-Pgp/Pgp (W/W)) : 25/1 N/P ratio




Figure 2: Transfection efficiency of various polyplexes in MCF 7 (FA+) and MBA-MB-435 (FA-) (N/P). N/P ratio: 25/1, FA-Pgp 1:2 = FA-Pgp/Pgp (w:w ratio), FA concentration in media: 750 µmol/L. (N=9) Data represents the mean ±SE.